Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.61 |
| ▸ | CA1 | P00915 | 9/20 | 0.61 |
| ▸ | CA2 | P00918 | 9/20 | 0.61 |
| ▸ | CA4 | P22748 | 5/20 | 0.61 |
| ▸ | CA5A | P35218 | 5/20 | 0.61 |
| ▸ | CA7 | P43166 | 5/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | P4HB | P07237 | 1/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18942030 | 1.00 | CA12 (0.61) | CA12CA1CA2CA4CA5A | |
| SCHEMBL21134954 | 1.00 | CA12 (0.61) | CA12CA1CA2CA4CA5A | |
| SCHEMBL22892186 | 1.00 | CA12 (0.61) | CA12CA1CA2CA4CA5A | |
| SCHEMBL18942039 | 1.00 | CA12 (0.61) | CA12CA1CA2CA4CA5A | |
| SCHEMBL3665513 | 0.92 | CA1 (0.50) | CA12CA1CA2CA4CA5A | |
| SCHEMBL23642758 | 0.91 | CA12 (0.72) | CA12CA1CA2CA4CA5A | |
| SCHEMBL20169037 | 0.91 | CA12 (0.72) | CA12CA1CA2CA4CA5A | |
| SCHEMBL22927973 | 0.91 | CA12 (0.72) | CA12CA1CA2CA4CA5A | |
| SCHEMBL18942413 | 0.91 | USP2 (0.51) | CA12CA1CA2CA4CA5A | |
| SCHEMBL1029421 | 0.91 | CA12 (0.72) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2021-01-14 | — | — | US | disclosed |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | OPKO PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | CA12 555/4885CA1 2138/4885CA2 2488/4885 |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | SI, GYS1, UGGT1 | CA12 555/4885CA1 2138/4885CA2 2488/4885 |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | CA12 555/4885CA1 2138/4885CA2 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.